{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:05:58Z","timestamp":1777557958072,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-16069428"],"award-info":[{"award-number":["RS-2025-16069428"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Vascular Disease Research"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been studied for their effects on cardiovascular disease, cognitive impairment, dementia, Parkinson\u2019s disease, and cerebrovascular disease, with evidence suggesting a reduced risk of mortality. This study aimed to examine the association between SGLT2 inhibitors and cerebrovascular event recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The cohort was extracted from the Korean National Health Insurance Service Database, including individuals aged 19 or older diagnosed with type 2 diabetes. SGLT2 inhibitor users were compared with metformin users using 1:4 propensity score matching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among study subjects, 1563 (7.8%) experienced recurrent cerebrovascular events. SGLT2 inhibitor users showed lower recurrence of cerebral infarction compared to metformin users (adjusted hazard ratio=0.84, p=0.010). Among the types of cerebrovascular diseases, ischemic stroke was associated with a significantly lower risk of recurrence in SGLT2 inhibitor users than metformin users (aHR=0.70, p=0.020). In the SGLT2 inhibitor group, concurrent use of DPP4 inhibitors was associated with a reduced risk of cerebrovascular event recurrence (aHR=0.69, p=0.011).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2 inhibitor use was associated with a significantly lower risk of recurrent cerebral infarction compared to metformin, suggesting a potential role in the secondary prevention of cerebrovascular events in patients with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/14791641261431777","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T21:23:55Z","timestamp":1772486635000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between SGLT2 inhibitors and recurrence of cerebrovascular events in patients with type 2 diabetes: A population-based cohort study"],"prefix":"10.1177","volume":"23","author":[{"given":"Mee Hyeon","family":"Kim","sequence":"first","affiliation":[{"name":"Chungbuk National University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Yeon","family":"Gil","sequence":"additional","affiliation":[{"name":"Chungbuk National University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Hyun","family":"Min","sequence":"additional","affiliation":[{"name":"Chungbuk National University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Hyeob","family":"Kim","sequence":"additional","affiliation":[{"name":"Chungbuk National University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Hyuk","family":"Park","sequence":"additional","affiliation":[{"name":"Chungbuk National University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunny","family":"Park","sequence":"additional","affiliation":[{"name":"Chungbuk National University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Min","family":"Han","sequence":"additional","affiliation":[{"name":"Chungbuk National University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9535-7314","authenticated-orcid":false,"given":"Kyung Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"Chungbuk National University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2017.09.019"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1943"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-016-0187-5"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.010389"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.0103"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319878371"},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"e0244689","DOI":"10.1371\/journal.pone.0244689","article-title":"Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis","volume":"16","author":"Li CX","year":"2021","unstructured":"Li CX, Liang S, Gao L, et al. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PLOS ONE 2021; 16: e0244689. https:\/\/doi.org\/10.1371\/journal.pone.0244689","journal-title":"PLOS ONE"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-020-00211-6"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237213"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000584"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S010"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.128"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14329"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040144"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000339763"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-020-00669-5"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10439-008-9508-x"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.4097\/kjae.2016.69.6.555"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101474"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02090-9"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00155-4"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_908_24"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/10742484241301191"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-020-0410-8"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13237093"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05498-0"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03605-4"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18269"}],"container-title":["Diabetes &amp; Vascular Disease Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/14791641261431777","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/14791641261431777","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/14791641261431777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:20:20Z","timestamp":1777400420000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/14791641261431777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/14791641261431777"],"URL":"https:\/\/doi.org\/10.1177\/14791641261431777","relation":{},"ISSN":["1479-1641","1752-8984"],"issn-type":[{"value":"1479-1641","type":"print"},{"value":"1752-8984","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"14791641261431777"}}